A
ABIVAX Société Anonyme (ABVX)
NGM – Real Time Price. Currency in USD
121.39
-0.74 (-0.61%)
At close: May 12, 2026, 4:00 PM EDT
121.49
+0.10 (0.08%)
After-hours: May 12, 2026, 7:42 PM EDT
Find any stock by ticker or company name

NGM – Real Time Price. Currency in USD
121.39
-0.74 (-0.61%)
At close: May 12, 2026, 4:00 PM EDT
121.49
+0.10 (0.08%)
After-hours: May 12, 2026, 7:42 PM EDT
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.
| Name | Position |
|---|---|
| Chris Rabbat Ph.D. | VP & Global Head of Medical Affairs |
| Hema Keshava | Senior Vice President of Finance |
| Kevin Shan Ph.D. | VP & Global Head of Biometrics |
| Mary Mantock | Senior VP & Global Head of Regulatory Affairs |
| Mr. Didier Blondel | EVP, CFO & Board Secretary |
| Mr. Jerome Denis Ph.D. | Executive Vice President of Process Development & Manufacturing |
| Mr. Marc M. P. de Garidel M.B.A. | CEO & Director |
| Mr. Patrick Malloy | Senior Vice President of Investor Relations |
| Mr. Pierre Courteille M.B.A. | Chief Business Officer |
| Ms. Ida Hatoum | Chief People & Compliance Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 6-K | d148287d6k.htm |
| 2026-04-20 | 6-K | abivax-6xkpreparatorydocum.htm |
| 2026-03-23 | S-8 | d13364ds8.htm |
| 2026-03-23 | 20-F | abvx-20251231.htm |
| 2026-02-23 | 6-K | a6-kxeccopr.htm |
| 2025-12-15 | 6-K | abvx-20250930.htm |
| 2025-09-08 | 6-K | abvx-20250630.htm |
| 2025-07-23 | F-3ASR | d944622df3asr.htm |
| 2025-07-22 | 6-K | d56921d6k.htm |
| 2025-06-11 | 6-K | a6-kcoverpagex060925pressr.htm |